Eptifibatide Cas:188627-80-7

Eptifibatide (Integrilin, Millennium Pharmaceuticals, Também co-promovido por Schering-Plough/Essex), é um medicamento antiplaquetário da classe inibidora da glicoproteína IIB/IIIa.[1] O eptifibatida é um heptapeptídeo cíclico derivado de uma proteína encontrada no veneno do sudeste de cascavel pigmeu (Sisturus Miliarius Barbouri). Pertence à classe dos chamados arginina-glicina-aspartato-miméticos e se liga reversivelmente às plaquetas. Eptifibatide tem uma meia-vida curta. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.

Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e.g., non-Q-wave) myocardial infarction (ou seja, non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI). The drug is usually applied together with aspirin or clopidogrel and (low molecular weight or unfractionated) heparin. Adicionalmente, the usual supportive treatment consisting of applications of nitrates, beta-blockers, opioid analgesics and/or benzodiazepines should be employed as indicated. Angiographic evaluation and other intensive diagnostic procedures may be considered a first line task before initiating therapy with eptifibatide. The drug should exclusively be used in hospitalized patients both because of the serious degree of patients’ illness and because of the possible side-effects of eptifibatide.